Cetuximab/TPF/radiotherapy in oesophageal cancer

ConclusionsNeoadjuvant cetuximab/TPF followed by chemoradiotherapy in locoregional oesophageal carcinoma patients is feasible and offers a modest response rate in this trial. The results of combining trimodality neoadjuvant treatment with cetuximab are consistent with the literature.Registration: The study is registered atClinicalTrials.gov (NCT00733889).
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research